Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels-Reference-Cited by-同舟云学术

Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels

Published:2016-09 Issue:9 Volume:60 Page:5595-5599
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Prattes Jürgen¹²,Duettmann Wiebke¹³,Hoenigl Martin¹²⁴⁵^ORCID

Affiliation:

1. Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz, Graz, Austria

2. Center for Biomarker Research in Medicine, Graz, Austria

3. Division of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

4. Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

5. Division of Infectious Diseases, Department of Medicine, University of California San Diego, San Diego, California, USA

Abstract

ABSTRACT Low posaconazole plasma concentrations (PPCs) have been associated with breakthrough invasive fungal infections. We assessed the correlation between pre-steady-state PPCs (obtained between days 3 and 5) and PPCs obtained during steady state in 48 patients with underlying hematological malignancies receiving posaconazole oral-solution prophylaxis. Pre-steady-state PPCs correlated significantly with PPCs obtained at steady state (Spearman r = 0.754; P < 0.001). Receiver operating characteristic (ROC) curve analysis of pre-steady-state PPCs revealed an area under the curve (AUC) of 0.884 (95% confidence interval [CI], 0.790 to 0.977) for predicting satisfactory PPCs at steady state.

Funder

Merck Investigator Studies Program

Oesterreichische Nationalbank

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00389-16

Reference36 articles.

1. Posaconazole’s impact on prophylaxis and treatment of invasive fungal infections: an update

2. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort